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The use of valproate has traditionally been held to be associated with a greater incidence of weight gain than that 
of other anticonvulsants. This paper presents an analysis of body weight data gathered during d randomized trial 
comparing valproate with carbamazepine in 260 children aged 4-15 years with newly-diagnosed epilepsy. There 
were more reports of weight gain as an adverse event in the valproate group than in the carbamazepine group (22 
reports in 14 patients vs. nine reports in five patients). However, amongst the 211 patients (103 on valproate and 
108 on carbamazepine) in whom objective weight measurements were taken during treatment, there were no 
differences between the treatments in percentage weight gain from baseline or incidence of excessive weight 
velocity. Eight patients reporting weight gain on valproate were switched to carbamazepine because of poor seizure 
control and/or adverse events including weight gain, but three of the four patients for whom body weight 
measurements were available continued to gain weight on carbamazepine. It is concluded that weight gain may be 
erroneously attributed to valproate treatment. 
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INTRODUCTION 
Sodium valproate is a well-established therapy in 
the treatment of epilepsy’. It has been shown to 
be as effective as carbamazepine in the treatment 
of both adult-onset2 and paediatric3.J epilepsy 
against both generalized and partial seizures. In 
addition, it has been associated with a lower 
incidence rate of side-effects necessitating its 
withdrawal as compared to phenytoin or pheno- 
barbitone in paediatric patient?. 
Weight gain has traditionally been regarded as 
a side-effect characteristic of valproate therapy, 
although its reported incidence has varied widely, 
ranging from 7.5%” to 73.0%h in early studies. 
This may be an unacceptable side-effect for some 
patients, in particular teenage girls’, in whom 
weight gain may lead to termination of sodium 
valproate treatment; paediatric studies have also 
reported weight gain (in from approximately 
10%’ to 44%’ of patients). Since the medical 
profession does not associate weight gain with 
other anticonvulsants (such as carbamazepine”) 
to the same extent, its occurrence in patients on 
valproate may lead to a switch of maintenance 
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therapy, with the possibility of the patient 
suffering other side-effects from the new 
medication. 
The reporting of side-effects in clinical practice 
and open studies may be influenced by patient 
and clinician expectations, and if a drug is 
perceived to be associated with a particular effect 
any occurrence of it during treatment may be 
more likely to be attributed to the drug. 
Conversely, weight gain occurring during treat- 
ment with a drug for which this side-effect is not 
expected may be overlooked. This paper reports 
on objective measures of weight gain, recorded as 
part of the paediatric EPITEG trial which 
compared sodium valproate with carbama- 
zepine”, in order to investigate the presence and 
extent of any subjective response. 
METHODS 
A full description of the paediatric EPITEG trial 
has been published elsewhere3. This paper 
presents a retrospective analysis of the body 
weight data recorded during the study. 
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The open, randomized study was conducted at 
63 outpatient clinics in the UK and the Republic 
of Ireland. Two hundred and sixty children (4-15 
years) with newly-diagnosed primary generalized 
epilepsy or partial epilepsy, with or without 
secondary generalization, participated in the 
study. Children with renal, hepatic, or other 
central nervous system disorders were excluded, 
as were children with abnormal liver function 
tests or blood dyscrasias, and girls taking con- 
traceptive medication at entry. 
Patients were randomized to receive either 
sodium valproate (initial dose 200 mg twice daily, 
increasing by 200 mg daily if clinically necessary, 
to a maximum of 30mg/kg daily), or car- 
bamazepine (initial dose 5 mg/kg daily, increas- 
ing in the second week of treatment to 10 mg/kg 
daily, and thereafter as clinically necessary to a 
maximum of 20 mg/kg daily). Failure of seizure 
control or occurrence of adverse events permitted 
cross-over to the alternative therapy. Any child 
requiring additional anticonvulsant medication 
was withdrawn from the study. Patients were 
assessed after one month of treatment, then at 
3-monthly intervals for the first year, and at 
approximately 6-monthly intervals thereafter for 
the remainder of the trial. The total period of 
follow-up was 3 years. 
Measurements of body weight taken at each 
visit were used for the present analysis. Patients 
were excluded if weight data were not available at 
baseline, or available only at baseline. If a patient 
crossed to the alternative treatment, only body 
weight data pertaining to the first treatment were 
included in the analysis, although changes in 
weight measured after transfer to the alternative 
drug were considered on an individual basis. 
Since the drop-out rate beyond one year was 
high, only data for the first 13 months were used. 
Patients were subgrouped by age (4-6 years, 7-9 
years, lo-12 years and 13-1.5 years) and sex, 
since growth rates and average body mass indices 
vary according to these parameters. 
Weight velocity was calculated for each patient 
as the change in body weight over or extrapolated 
to one year. Weight velocity was classed as 
‘excessive’ if it exceeded the 97th centile expected 
for a child of that age and sex (as defined by 
Egger and Brett’). If the body weight data for any 
patient was only available for a period of less than 
11 months, but weight velocity extrapolated to 
one year exceeded the 97th centile, it was classed 
as ‘probably excessive’. The incidence of patients 
displaying excessive weight velocity was com- 
pared between the treatment groups by calculat- 
ing odds ratios. 
Any patient with a body mass index [BMI; 
weight (kg)/height (m)‘] at study entry higher 
than the 90th centile for their age and sex (as 
defined by Cronk and Roche’) was classed as 
obese. 
RESULTS 
Percentage weight gain from baseline 
From a total of 260 patients originally enrolled in 
the EPITEG trial, 211 with adequate body weight 
records were eligible for this analysis, listing 
weight measurements for at least one month after 
baseline. Of the 103 patients in the valproate 
group and 108 patients in the carbamazepine 
group, 11 (10.7%) and 11 (10.2%) respectively, 
were classifiable as obese at study entry. 
There was no consistent difference between the 
two treatment groups with respect to mean 
percentage changes in body weight from baseline 
over the four age ranges (Fig. 1). 
Incidence of excessive body weight velocity 
Body weight velocity was calculated for 203 
patients (eight patients, four from each treat- 
ment, were excluded either because they were off 
treatment or no weight measurements were taken 
after 1 month). The risks of excessive or probably 
excessive weight velocities analysed by sex and 
treatment group are shown in Table 1. The data 
suggest that risk of excessive velocity slightly 
increases with valproate for males and with 
carbamazepine for females, however, no real 
differences could be established between the two 
drugs. 
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Fig. 1: Mean percentage weight gain from baseline in 
children with epilepsy during treatment with sodium 
valproate (n = 103) or carbamazepine (n = 108). X, Sodium 
valproate; 0, carbamazepine. 
Weight gain with valproate or carbamazepine 
Table 1: Risks of excessive or probably excessive weight velocities by sex and treatment group 
Sodium valproate Carbamazepine Odds ratio 
% (n/N) % (n/N) 
Males 32.6 (15/46) 28.0 (14/50) 1.24 
Females 20.8(11/53) 29.6 ( 16/54) 0.62 
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intervals 
0.52,2.98 
0.26,1.51 
Reported body weight gain 
Of the 260 patients originally enrolled in this 
study, 12 patients (9.2%) who received valproate 
as initial therapy reported weight gain as an 
adverse event on 18 occasions, compared with 
five patients (3.8%) who initially received car- 
bamazepine on nine occasions. A further two 
patients reported weight gain on four occasions 
after having been switched from carbamazepine 
to valproate. Three patients (two on valproate; 
one on carbamazepine) reporting weight gain as 
an adverse event were excluded from the present 
analysis population due to insufficient weight 
data, while in three other cases (all on valproate) 
weight gain was not reported until after the 13 
month analysis period. Therefore, a total of eight 
patients (13 occasions) reporting weight gain 
during valproate therapy, and four patients (five 
occasions) during carbamazepine therapy, were 
included in the present analysis. All five of the 
carbamazepine reports of weight gain and 11 of 
the valproate reports corresponded to excessive 
weight velocity. 
Crossover between therapies 
The trial design permitted patients who failed on 
first treatment because of poor seizure control, 
adverse events, or both, to be crossed to the 
alternative treatment for the remainder of the 
3-year trial period. Full details of these treatment 
failures are given elsewhere3. 
Eight of the patients who reported weight gain 
while on valproate were later crossed over to 
carbamazepine. In two of these cases, no weight 
data were recorded on either drug; in a further 
two cases, no objective weight measurements 
were made after the switch to carbamazepine. Of 
the remaining four patients, only one showed a 
pattern consistent with valproate-induced weight 
gain. This 12-year-old girl was overweight at 
study entry (65 kg). After gaining a further 5 kg in 
6 months of valproate treatment she requested 
that treatment be stopped. She was transferred to 
carbamazepine and subsequently lost weight, 
reaching 52 kg by the 2-year follow-up visit. 
Another previously obese patient (a boy of 13 
years) was transferred to carbamazepine, but 
continued to gain weight after the changeover. 
Neither of the other two patients had stopped 
valproate treatment for weight-related reasons 
and the change of medication again had no 
apparent effect on their weight. 
DISCUSSION 
Various mechanisms have been postulated to 
explain weight gain in patients taking sodium 
valproate7*9-‘2, however, the present study does 
not support the perception that weight gain is an 
effect peculiar to the use of this drug. The present 
data indicate that valproate and carbamazepine 
have similar effects on weight when used to treat 
children with epilepsy. During the study from 
which the data used was taken3 more patients 
reported weight gain with valproate than with 
carbamazepine; however, analysis of objective 
measurements of weight, taken as part of the 
original trial protocol, shows no difference 
between the treatment groups with respect to 
percentage weight increase from baseline or 
incidence of excessive weight velocity. Indeed, in 
girls (for whom weight gain is often quoted as 
being an unacceptable side-effect’) there was a 
trend to a lower incidence of excessive weight 
velocity in the valproate-treated group (see 
Table 1). 
In open studies and clinical practice observer 
bias cannot be eliminated as it can be in 
double-blind trials. A perception that sodium 
valproate is more likely to cause weight gain may 
lead to observed weight gain in a valproate- 
treated child being attributed to the drug even 
though the treatment may have been only a 
contributory factor. The data reported here show 
some indication of this effect. Of those reports 
made during the first 13 months on treatment, 
where objective weight measurements were 
available, two during valproate therapy did not 
correspond to excessive weight velocity. This 
suggests that in these cases normal growth had 
been mistakenly interpreted as a side-effect of 
valproate. 
Another possible effect of observer bias in the 
original study3 was an apparent under-reporting 
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of excessive weight gain associated with car- 
bamazepine. The number of such reports as- 
sociated with carbamazepine was much lower 
than that with valproate even though there were 
no differences with the number of patients with 
excessive and probably excessive weight velo- 
cities between the two treatment groups. 
The individual records of the patients reporting 
weight gain during valproate therapy who subse- 
quently changed to carbamazepine, also suggest 
that valproate may be less important as a cause of 
weight gain than is generally supposed. Three of 
the four patients for whom objective weight 
measurements were available during both treat- 
ments showed no dramatic change in their rate of 
weight gain after cross-over. The fourth patient 
lost a substantial amount of weight during 
carbamazepine treatment, eventually reaching a 
normal weight after having been overweight at 
study entry. Had her excess weight been due 
entirely to valproate treatment, it is unlikely that 
withdrawing the drug would have reduced her 
weight to less than it was at the start of therapy. 
Her weight loss may have been caused, at least in 
part, by other factors such as developmental 
changes. 
The finding of the present report-that the 
incidence of weight gain associated with valproate 
treatment may be exaggerated and may be no 
different from that associated with car- 
bamazepine treatment-is at variance with the 
conclusions drawn by other studiesS.7.‘3.‘4. In 
particular, a double blind, randomized trial 
comparing valproate with carbamazepine in 
adults” found a significantly greater incidence of 
excessive weight gain associated with valproate 
vs. carbamazepine. However, that trial utilized 
patients from a very specific population: pre- 
dominantly adult male war veterans, 31% of 
whom had trauma-related epilepsy. The 
difference between this population and the one 
used in the present study may explain the 
disparity between the results. 
One obvious drawback of the present study is 
its open nature. Weight data were not recorded 
on all study visits in the original trial3 which led to 
patients being excluded from the present analysis. 
Moreover, the irregular frequency with which 
height data were recorded precluded more 
detailed analyses involving BMI, rather than 
weight, as a variable. It also would have been 
useful to compare data from the adult EPITEG 
trial*, however, weight data are not available to 
enable this analysis to be made. Notwithstanding, 
the present study raises serious doubts about the 
traditionally-held view concerning the incidence 
of weight gain with this widely-used antiepileptic 
agent. It is suggested that this issue should be 
addressed by any future prospective, double- 
blind, randomized trial involving valproate 
and/or carbamazepine in a wider population of 
patients. 
CONCLUSIONS 
This study, the first to compare the effects of 
sodium valproate and carbamazepine on objec- 
tive measures of weight gain, found that sodium 
valproate may be no more likely than car- 
bamazepine to be associated with weight gain 
when used to treat children with epilepsy. Weight 
gain due to other factors, such as existing 
adiposity or a normal growth spurt, may be 
erroneously attributed to sodium valproate, and 
that occurring during carbamazepine may be 
overlooked. Clinicians should consider all pos- 
sible reasons for an observed increase in weight 
before deciding to switch the patient to a new 
anticonvulsant, since inappropriate changing of 
the patient’s medication may result in further 
side-effects caused by the new drug. 
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